Introduction
Increased drug levels in patients with hepatitis coinfection have been repeatedly discussed as the underlying causes for an increased risk of nevirapine-related liver injury. Whereas several trials have addressed this issue and correlated hepatitis coinfection status and/or degree of hepatic insufficiency to random nevirapine drug levels, up to now no data on complete pharmacokinetic analysis exist. 1 -4 In the current study, we thus performed a complete 12 h pharmacokinetic analysis in order to investigate the differences in the nevirapine metabolism of HIV/hepatitis C virus (HCV)-coinfected and HIV-monoinfected patients.
Methods
Patients HIV-monoinfected or HIV/HCV-coinfected patients who were on a stable nevirapine-containing highly active antiretroviral therapy (HAART) for more than 4 weeks were included. Nevirapine was dosed at 200 mg twice daily for all subjects. Liver disease other than chronic HCV had to be ruled out. Advanced liver disease was excluded by a normal ultrasound of the liver and spleen within the past 3 months. Moreover, laboratory and clinical assessment for Child -Pugh score had to be 5 points (lowest possible value). Patients were excluded in case of active AIDS-defining or other severe illness, gastrointestinal malabsorption, known or suspected non-adherence to HAART, or taking any co-medication influencing nevirapine pharmacokinetics.
All participants were admitted to our day clinic for a 12 h pharmacokinetic study. After a first blood withdrawal in a fasting state, a standardized breakfast (610 kcal; 16% protein/33% fat/51% carbohydrates) together with one tablet of 200 mg of nevirapine was taken, and consecutive blood withdrawals for pharmacokinetic sampling were taken at 1, 2, 4, 6 and 12 h thereafter. All participants had given prior written informed consent. The study was approved by the local Ethics Committee and was conducted in agreement with good clinical practice and the declaration of Helsinki and its subsequent revisions. 
Nevirapine plasma levels and pharmacokinetic model
All standard laboratory tests were performed at the Bonn University Department of Clinical Chemistry and the Institute of Microbiology and Immunology within the clinical routine. Nevirapine plasma levels were determined via a validated gas chromatography/mass spectrometry (GC/MS) method. Briefly, after the precipitation of proteins with acetonitrile, the organic phase was extracted with dichloromethane. For the determination and quantification of nevirapine, 1 mL of the organic phase was injected into the GC/MS system (GAS Chromatograph, Fisons GC 8065 and mass spectrometer, Fisons MD 800; Thermo Fisher Scientific Inc., Waltham, MA, USA). Linear calibration curves were obtained with BIRH 0414BS as an internal standard in a dynamic range from 0.01 to 15 mg/mL. Extraction efficacy from 500 mL of human plasma spiked with 4 mg/mL nevirapine was 98%. Across four different concentrations of nevirapine (1, 2, 5 and 7 mg/mL), intra-and interday accuracy and precision were 96% to 109% and 1.7% to 5.2%, respectively. Plasma concentrations versus time were analysed under the assumption of a non-compartmental pharmacokinetic model and steady-state conditions with oral intake of 200 mg of nevirapine every 12 h.
The highest nevirapine plasma concentration was defined as C max with the corresponding timepoint T max . Correspondingly, the lowest nevirapine plasma concentration was defined as C min with the corresponding timepoint T min . The area under the curve (AUC) was calculated using pharmacokinetic software WinNonlin 5.2 (Pharsight Inc., Mountain View, CA, USA).
Statistics
Based on a previous study, 5 a sample size of 12 patients for each arm was calculated to be sufficient in order to detect a difference of 50% of C max with a power of 0.7 and an alpha of 0.05. Fisher's exact and Mann-Whitney U-test using SPSS 14.0 (SPSS Inc., Chicago, IL, USA) were used for calculation of statistical comparisons.
Results
Eighteen patients were recruited into the study: 7 patients with HIV/HCV coinfection and 11 with HIV monoinfection.
Comparison of HIV/HCV-coinfected patients with HIVmonoinfected patients showed no differences with regard to general demographic parameters (Table 1) . Except for significantly higher liver transaminases, HIV/HCV-coinfected patients showed comparable parameters of synthetic liver function and HIV surrogate markers to HIV-monoinfected patients.
Comparing pharmacokinetic parameters, no differences were observed comparing minimum nevirapine plasma concentrations, as well as AUC of nevirapine, between the HIV-monoinfected and HIV/HCV-coinfected patients (Table 1) . Importantly, no difference was observed between the groups concerning the maximum nevirapine plasma level (Figure 1 ).
Discussion
Hepatitis coinfection and raised transaminases have been repeatedly shown as independent risk factors for drug-related injury under HAART. For direct drug-related hepatotoxicity, raised nevirapine plasma levels in HIV/HCV-coinfected patients or patients with advanced liver disease have been observed and held responsible for this phenomenon.
1,2,6
However, in our study, we were able to compare HIVmonoinfected and HIV/HCV-coinfected patients by means of a full pharmacokinetic analysis. Importantly, HIV-monoinfected and HIV/HCV-coinfected patients were comparable, with regard to liver function and degree of liver fibrosis/cirrhosis so that only the impact of chronic viral hepatitis on the pharmacokinetics of nevirapine was studied. In our analysis, no differences with respect to any of the pharmacokinetic parameters were observed. In particular, C max , which is commonly held responsible for direct toxic effects, 7 was not different between the two groups. Therefore, Values are given as number of patients (%) or as median (range). ALT, alanine aminotransferase; INR, international normalized ratio; C min , minimum concentration of nevirapine; C max , maximum concentration of nevirapine; AUC 0 -12 , area under the curve over the observed 12 h dosing interval.
a ALT values are shown in italics as ALT was significantly higher in HIV/HCV-coinfected patients compared with HIV-monoinfected patients.
Nevirapine pharmacokinetics other factors, not related to different pharmacokinetics, appear to be responsible for an increased risk of liver damage in HIV/HCV-coinfected patients. Recently, it has been suggested that concurrent viral infections may aggravate drug-induced liver injury by activating the hepatic innate immune system to produce proapoptotic factors. 8 Apart from this, HCV coinfection may have served as a surrogate marker for liver insufficiency in older studies. HCV infection in HIV-infected patients takes a more rapid course and leads more quickly to advanced liver fibrosis and cirrhosis than in the HIV-negative population and is thus increasing in prevalence among HIV/HCV-coinfected patients. Indeed, newer studies show that liver fibrosis and cirrhosis, but not chronic hepatitis per se, are associated with higher risk for antiretroviraldrug-associated liver injury. 6 Observed pharmacokinetic data were within the range of previously published data, which report median (inter-quartile range) of: C min , 3.7 mg/mL (3.2 -5.1); and C max , 5.7 mg/mL (5.0 -7.4). 5 However, one subject presented with very low C min concentrations, and moreover had a detectable viral load despite being on HAART for more than 1 year. Despite our protocol and thorough interview of participants regarding their adherence, with this patient we may have included a non-adherent candidate in error. After exclusion of this patient, our analysis on comparison of both HIV-infected and HIV/HCV-coinfected patients did not change, however, so that this error appears insignificant. On the other hand, two participants showed C max values more than 2-fold above the range previously reported. 5 None of these patients had co-medications with known drug-to-drug interactions with nevirapine that would have explained this finding. Though not the primary intention of our study, we investigated a possible relationship between high plasma levels and raised alanine aminotransferase. However, in our small cohort, we were not able to find a relationship. This may not preclude, however, that in individual cases high nevirapine plasma levels may have a toxic effect on the liver as described previously. 9 There are some limitations to our study. Unfortunately, we were not able to fully recruit our study so that the power to detect differences between the two study groups may be limited. A detectable alternative hypothesis H1 was post hoc calculated to be 5 mg/mL for C max , i.e. with the given data, a mean difference of 5 mg/mL C max or more would not have been overlooked comparing the two groups. Moreover, C min , C max and AUC were overall lower in HIV/HCV-coinfected than in HIV-monoinfected patients (Table 1 and Figure 1) . In order to be causally related to drug-related liver injury, C max , C min or AUC of nevirapine would be expected to be higher in HIV/HCV-coinfected than in HIV-monoinfected patients. Thus, despite not meeting the recruitment goal of our study, our data should be valid to perform the above analysis.
Conclusions
Nevirapine pharmacokinetics may change over the course of time. Our study is the first to undertake a full pharmacokinetic analysis of HIV/HCV-coinfected patients who have been on nevirapine for longer periods of time, i.e. .4 weeks. In isolated cases, we observed increased C max values 2-fold above those of historical cohorts, though this increase was not associated with any signs of liver-related injury. However, our study highlights the possibility of accumulating drug levels under nevirapine therapy, and thus pharmacokinetic measurement in individual cases with suspected nevirapine-associated hepatotoxicity may be warranted.
Whereas hepatitis C infection is associated with an increased risk of hepatotoxicity, in our study we were not able to show any change in pharmacokinetics between patients with and without chronic hepatitis C infection as a possible cause for direct drug-related liver injury. As previous studies have shown, caution may be warranted, however, in patients with advanced liver fibrosis or cirrhosis. 
